Phase 2 Trial of NEU-411 for LRRK2-Driven Disease Begins Dosing

Neuron23 has officially dosed the first participant in a Phase 2 clinical trial of NEU-411, a potential new treatment for early-stage Parkinson’s disease. This treatment specifically targets overactivity in the LRRK2 enzyme, which plays a key role in both inherited and some non-inherited forms of Parkinson’s. 🔍 Who Might Benefit? NEU-411 may be especially helpful for people with certain genetic mutations or variations (SNPs) in the LRRK2 gene, which is linked to disrupted cell processes and inflammation in the brain. While only about 2% of Parkinson’s cases are inherited through LRRK2 mutations, up to 30% of people with non-inherited Parkinson’s may still have overactive LRRK2 enzymes. 🧪 A Personalized Approach to Treatment Neuron23 is using at-home saliva-based genetic testing to identify approximately 150 participants—ages 50 to 80—who are most likely to respond to NEU-411. This marks the first time a precision medicine approach is being used in a Parkinson’s trial to specifically target LRRK2 activity. 💊 What Is NEU-411? NEU-411 is a small oral medication designed to safely reduce LRRK2 enzyme activity. It was shown to be well tolerated in an earlier Phase 1 trial in healthy adults. 📱 Digital Tools for Real-Time Tracking Participants will take either NEU-411 or a placebo once daily for 52 weeks. During the study, researchers will use smartphone-based digital biomarkers, developed by Roche, to monitor real-time changes in movement, tremors, cognition, and other motor and non-motor symptoms. Participants will also receive standard neurological evaluations. 🧪 What’s Next? The trial, called NEULARK (NCT06680830), is now enrolling in the U.S. and will expand globally. Safety will be closely monitored throughout and for two weeks after treatment ends. 💡 Why This Matters This study represents a milestone in Parkinson’s research—offering a targeted, personalized approach and using digital tools to better understand disease progression. For those living with Parkinson’s, it brings hope for more precise, effective treatments that go beyond symptom management.